Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026)
Azitra (AZTR) reported Liabilities and Shareholders Equity of $12.1 million for Q1 2026, up 105.26% on a YoY basis from $5.9 million in Q1 2025, and up 141.31% quarter-over-quarter from $5.0 million in Q4 2025.
Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Azitra has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $12.1 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 105.26% year-over-year to $12.1 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (down 5.64% YoY), and the FY2025 full-year result was $5.0 million, down 31.71% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $12.1 million, up from $5.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $12.1 million in Q1 2026, with the low at $3.9 million in Q2 2024.
- Historically, Liabilities and Shareholders Equity has averaged $6.8 million across 5 years, with a median of $6.1 million in 2024.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 60.5% — and 2026, when it surged 105.26%.
- Azitra's Liabilities and Shareholders Equity stood at $7.2 million in 2022, then dropped by 28.63% to $5.1 million in 2023, then soared by 43.85% to $7.4 million in 2024, then sank by 31.71% to $5.0 million in 2025, then jumped by 141.31% to $12.1 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $12.1 million (Q1 2026), $5.0 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.13 Mn |
| Dec 31, 2025 | 5.03 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 3.96 Mn |
| Mar 31, 2025 | 5.91 Mn |
| Dec 31, 2024 | 7.36 Mn |
| Sep 30, 2024 | 9.78 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Mar 31, 2024 | 6.07 Mn |
| Dec 31, 2023 | 5.12 Mn |
| Sep 30, 2023 | 7.49 Mn |
| Jun 30, 2023 | 9.83 Mn |
| Dec 31, 2022 | 7.17 Mn |